FI933862A0 - Loesliga ligander foer cd40 - Google Patents

Loesliga ligander foer cd40

Info

Publication number
FI933862A0
FI933862A0 FI933862A FI933862A FI933862A0 FI 933862 A0 FI933862 A0 FI 933862A0 FI 933862 A FI933862 A FI 933862A FI 933862 A FI933862 A FI 933862A FI 933862 A0 FI933862 A0 FI 933862A0
Authority
FI
Finland
Prior art keywords
loesliga
ligander
foer
soluble ligands
promoting
Prior art date
Application number
FI933862A
Other languages
English (en)
Other versions
FI113969B (fi
FI933862A (fi
Inventor
Alejandro Aruffo
Diane Hollenbaugh
Jeffrey A Ledbetter
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25475138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI933862(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of FI933862A0 publication Critical patent/FI933862A0/fi
Publication of FI933862A publication Critical patent/FI933862A/fi
Application granted granted Critical
Publication of FI113969B publication Critical patent/FI113969B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Catalysts (AREA)
  • Saccharide Compounds (AREA)
FI933862A 1992-09-04 1993-09-03 Menetelmä CD40:n liukoisen ligandin valmistamiseksi, sitä koodaava nukleiinihappo ja sen käyttö FI113969B (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/940,605 US5540926A (en) 1992-09-04 1992-09-04 Soluble and its use in B cell stimulation

Publications (3)

Publication Number Publication Date
FI933862A0 true FI933862A0 (fi) 1993-09-03
FI933862A FI933862A (fi) 1994-03-05
FI113969B FI113969B (fi) 2004-07-15

Family

ID=25475138

Family Applications (1)

Application Number Title Priority Date Filing Date
FI933862A FI113969B (fi) 1992-09-04 1993-09-03 Menetelmä CD40:n liukoisen ligandin valmistamiseksi, sitä koodaava nukleiinihappo ja sen käyttö

Country Status (17)

Country Link
US (2) US5540926A (fi)
EP (1) EP0585943B1 (fi)
JP (1) JP3529815B2 (fi)
KR (1) KR100319126B1 (fi)
AT (1) ATE163195T1 (fi)
AU (1) AU677788B2 (fi)
CA (1) CA2105552C (fi)
DE (1) DE69316948T2 (fi)
DK (1) DK0585943T3 (fi)
ES (1) ES2113980T3 (fi)
FI (1) FI113969B (fi)
GR (1) GR3026100T3 (fi)
HU (1) HU215949B (fi)
IL (1) IL106896A (fi)
NO (1) NO311808B1 (fi)
NZ (1) NZ248569A (fi)
ZA (1) ZA936491B (fi)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US7405270B2 (en) * 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
CA2312667C (en) * 1991-10-25 2002-11-19 Immunex Corporation Novel cytokine
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
DK0679191T3 (da) * 1993-01-22 2004-04-13 Immunex Corp Påvisning og behandling af mutationer i et CD40-ligand-gen
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
ATE167062T1 (de) * 1993-09-02 1998-06-15 Dartmouth College Verfahren zur anregung antigenspezifischer t- zelltoleranz
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
WO1995014487A1 (en) * 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
US5674492A (en) * 1993-12-23 1997-10-07 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing CD40
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
JP3881691B2 (ja) 1994-04-28 2007-02-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｂ細胞の増殖方法及び分化方法並びにその使用
GB9425060D0 (en) * 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5645837A (en) * 1995-01-17 1997-07-08 Thomas Jefferson University Peptides that inhibit T cell activation and methods of using the same
WO1996028568A1 (en) 1995-03-13 1996-09-19 The Regents Of The University Of Michigan Cd40 binding compositions and methods of using same
DK0832229T3 (da) * 1995-06-07 2004-05-03 Immunex Corp CD40L-mutein
JPH11508262A (ja) * 1995-06-22 1999-07-21 バイオジェン，インコーポレイテッド Ｃｄ４０リガンドのフラグメントの結晶およびその使用
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
WO1997022256A1 (en) * 1995-12-19 1997-06-26 National Jewish Center For Immunology And Respiratory Medicine Method to regulate cd40 signaling
US6451995B1 (en) * 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
JP2002514047A (ja) * 1996-07-10 2002-05-14 イミュネックス・コーポレーション 樹状細胞を活性化する方法
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
KR100632846B1 (ko) * 1997-01-10 2006-10-16 바이오겐 아이덱 엠에이 인코포레이티드 치료를 위한 항ｃｄ40ｌ 화합물의 투여 방법
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
US20050031611A1 (en) * 1998-05-08 2005-02-10 Beth Israel Deaconess Medical Center Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
WO2000066155A1 (en) 1999-04-30 2000-11-09 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
CN100358577C (zh) 1999-05-07 2008-01-02 杰南技术公司 抗体在制备治疗哺乳动物自身免疫病的试剂中的用途
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
BR0013201A (pt) * 1999-07-12 2002-04-30 Genentech Inc Método de bloqueio de uma resposta imunológica a um antigeno externo em mamìferos através da utilização de um antagonista que se liga ao cd20, método de tratamento de mamìferos, método de tratamento de uma doença de enxerto contra hospedeiro ou hospedeiro contra enxerto em mamìferos, método de insensibilização de mamìferos que aguardam transplante e artigo industrializado
US6482411B1 (en) 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
WO2001026608A2 (en) * 1999-10-14 2001-04-19 Ledbetter Jeffrey A Dna vaccines encoding antigen linked to a domain that binds cd40
US20030077263A1 (en) * 1999-10-29 2003-04-24 Immunex Corporation Method of activating dendritic cells
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU2062601A (en) * 1999-12-06 2001-06-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Peptides that stabilize protein antigens and enhance presentation to CD8+ T cells
US20110041190A1 (en) * 2002-10-31 2011-02-17 Tykocinski Mark L Novel chimeric proteins
ATE511857T1 (de) * 2000-02-16 2011-06-15 Genentech Inc Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2422076A1 (en) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US7786257B2 (en) * 2000-12-18 2010-08-31 University Of Kansas Signal-1/signal-2 bifunctional peptide inhibitors
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20050070689A1 (en) * 2001-08-03 2005-03-31 Genentech, Inc. Taci and br3 polypeptides and uses thereof
US20030139374A1 (en) * 2001-09-27 2003-07-24 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coagulation and treatment
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
MXPA05000940A (es) * 2002-07-25 2005-05-16 Genentech Inc Anticuerpos taci y su uso.
KR100932340B1 (ko) * 2002-10-17 2009-12-16 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP1606313A2 (en) * 2003-03-19 2005-12-21 Isogenis, Inc. Specific inhibition of allograft rejection
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
JP2007526220A (ja) * 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド Ｂ細胞疾患の併用療法
JP5848861B2 (ja) * 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
CA2574802A1 (en) * 2004-07-20 2006-02-02 Isogenis, Inc. Specific inhibition of autoimmunity and diseases associated with autoantigens
MX2007001015A (es) 2004-07-26 2007-04-12 Biogen Idec Inc Anticuerpos anti-cd154.
WO2006062094A1 (ja) * 2004-12-07 2006-06-15 Toray Industries, Inc. 新規癌抗原ペプチド及びその用途
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
BRPI0610470A2 (pt) * 2005-05-26 2010-06-22 Seattle Genetics Inc anticorpo isolado ou fragmento de ligação a antìgeno que especificamente se liga a cd40 humano, kit, composição farmacêutica, e, polinucleotìdeo isolado
US9726673B2 (en) * 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
HUE047164T2 (hu) * 2007-11-01 2020-04-28 Univ Arkansas Kompozíciók és eljárások eimeria elleni immunválasz fokozására
US20110059078A1 (en) * 2008-02-08 2011-03-10 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
AU2009274502A1 (en) * 2008-07-25 2010-01-28 Theraclone Sciences, Inc. Methods and compositions for discovery of target-specific antibodies using antibody repertoire array (ARA)
WO2010014629A1 (en) * 2008-07-28 2010-02-04 Trubion Pharmaceuticals, Inc. Multi-specific binding proteins targeting b cell disorders
EP2342321B1 (en) * 2008-09-17 2018-04-11 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
WO2011041093A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
CA2812057A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
WO2013131045A1 (en) 2012-03-02 2013-09-06 The Regents Of The University Of California Expansion of alloantigen-reactive regulatory t cells
US9603915B2 (en) 2013-02-14 2017-03-28 The Board of Trustees of the University of Akansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
US20160075766A1 (en) 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
ES2944563T3 (es) * 2014-05-19 2023-06-22 Hoffmann La Roche Procedimiento para producir anticuerpos usando linfocitos B ovinos y usos de los mismos
WO2017079202A1 (en) 2015-11-02 2017-05-11 Board Of Regents, The University Of Texas System Methods of cd40 activation and immune checkpoint blockade
WO2021050789A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT53672A (en) * 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US5227167A (en) * 1991-06-11 1993-07-13 Alza Corporation Long-term delivery device including hydrophobic loading dose
CA2312667C (en) * 1991-10-25 2002-11-19 Immunex Corporation Novel cytokine
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
JP4242447B2 (ja) * 1993-01-22 2009-03-25 イミュネックス・コーポレーション Ｃｄ４０リガンド遺伝子の突然変異の検出および治療

Also Published As

Publication number Publication date
GR3026100T3 (en) 1998-05-29
CA2105552A1 (en) 1994-03-05
FI113969B (fi) 2004-07-15
JP3529815B2 (ja) 2004-05-24
HU9302484D0 (en) 1993-11-29
KR940007179A (ko) 1994-04-26
US5945513A (en) 1999-08-31
ZA936491B (en) 1994-03-25
IL106896A0 (en) 1993-12-28
ES2113980T3 (es) 1998-05-16
NO933126D0 (no) 1993-09-02
JPH06315383A (ja) 1994-11-15
CA2105552C (en) 2009-08-18
EP0585943A3 (en) 1994-07-06
NO933126L (no) 1994-03-07
EP0585943B1 (en) 1998-02-11
HU215949B (hu) 1999-03-29
AU4612093A (en) 1994-03-10
KR100319126B1 (ko) 2002-05-13
IL106896A (en) 2005-12-18
NO311808B1 (no) 2002-01-28
HUT69977A (en) 1995-09-28
AU677788B2 (en) 1997-05-08
DE69316948T2 (de) 1998-10-01
US5540926A (en) 1996-07-30
EP0585943A2 (en) 1994-03-09
NZ248569A (en) 1995-10-26
FI933862A (fi) 1994-03-05
ATE163195T1 (de) 1998-02-15
DK0585943T3 (da) 1998-09-23
DE69316948D1 (de) 1998-03-19

Similar Documents

Publication Publication Date Title
DK0585943T3 (da) Opløselige ligander for CD40
DE3779346D1 (de) Zusammensetzung zur behandlung der haut.
DE69703649T2 (de) Behandlung von deagglomerierten teilchen mit plasmaaktivierter spezies
BE2012C001I2 (fi)
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
ATE222769T1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
DE58905201D1 (de) Mittel zur behandlung des parkinson-syndroms.
FR2491334B1 (fi)
DE3782214D1 (de) Mittel zur behandlung des scheidenmilieus.
ATE347372T1 (de) Vakzine zur behandlung von mycosen
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
EP0325129A3 (en) Disubstituted pyridines
DE3777656D1 (de) Mittel zur behandlung von alopezien.
EP0647138A4 (en) POLYPEPTIDES AVAILABLE FROM FASCIOLA SPECIES, AND VACCINE, THERAPY PROCEDURES AND DNA SEQUENCES ENCODING THESE PEPTIDES.
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
DE69000960D1 (de) Zusammensetzung zur behandlung von pigmentierung.
DE68908445T2 (de) Mittel zur Behandlung von Lebererkrankungen.
FI971879A0 (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
DE69002821D1 (de) Zusammensetzung zur haarbehandlung.
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.
ITTO920049A1 (it) Apparecchio e metodo per il trattamento di tessuti, in particolare tessuti adiposi.
DE29600841U1 (de) Vorrichtung zur thermischen Behandlung von Gegenständen
ATE92763T1 (de) Mittel zur behandlung des parkinson-syndroms.
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ATE91886T1 (de) Praeparat zur behandlung von erektionsstoerungen.

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed
MA Patent expired